What is BetterLife Pharma Inc. (BETRF) stock price today?

BetterLife Pharma Inc. (BETRF) is currently trading at $0.15, down 7.5% today.

What is BETRF P/E ratio?

BetterLife Pharma Inc.'s P/E ratio is -16.80. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is BETRF return on equity (ROE)?

BetterLife Pharma Inc.'s return on equity (ROE) is 19.88%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is BetterLife Pharma Inc.'s market cap?

BetterLife Pharma Inc. has a market capitalization of $23.96M.

OTC · Biotechnology

BetterLife Pharma Inc. (BETRF) Stock

$0.15 -7.50% OTC: BETRF Healthcare

Valuation

Metric	Value
Price	$0.15
Market Cap	$23.96M
P/E Ratio	-16.80
P/B Ratio	-3.33
P/S Ratio	0.00
EPS (TTM)	$-0.01
52-Week High	$0.20
52-Week Low	$0.03
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	19.88%
ROA	-780.97%
ROCE	29.80%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.11
Current Ratio	0.04

Annual Financials (USD)

Metric	2022	2023	2024	2025	2026
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-10.0M	$-9.0M	$-3.0M	$-5.0M	$-2.0M
Net Profit	$-12.0M	$-9.0M	$-3.0M	$-4.0M	$-1.0M
EPS	$-0.16	$-0.10	$-0.03	$-0.03	$-0.01
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2022	2023	2024	2025	2026
Total Assets	$1.0M	$0	$0	$0	$0
Total Liabilities	$5.0M	$8.0M	$8.0M	$8.0M	$7.0M
Cash	$0	$0	$0	$0	$0
Borrowings	$1.0M	$1.0M	$1.0M	$1.0M	$1.0M

Latest News

BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism TMX Newsfile · Jul 13, 2026 BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee TMX Newsfile · Jul 9, 2026 BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1 TMX Newsfile · Jul 6, 2026 BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1 TMX Newsfile · Jun 25, 2026 BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing TMX Newsfile · Jun 22, 2026

Cash Flow (USD)

Metric	2022	2023	2024	2025	2026
Operating Cash Flow	$-11.0M	$-2.0M	$-2.0M	$-2.0M	$-1.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$1.0M	$2.0M	$0	$0
Net Cash Flow	$0	$0	$0	$0	$0
Free Cash Flow	$-11.0M	$-2.0M	$-2.0M	$-2.0M	$-1.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.13
EV / EBITDA	-19.03
FCF Yield	-2.50%
Quick Ratio	0.04
Interest Coverage	-10.34
Return 1Y	127.69%
Return 3Y	174.07%
Return 5Y	—

Ownership

Insiders Held33.63%

Institutions Held0.00%

Institutions Float Held0.00%

Institutional Holder	Shares	Report Date
Bartlett & Co.	4,000	2023-12-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BNXT.CNBioNxt Solutions Inc.	$0.33	-13.16%	-4.86	$47.63M	0.00%
CYBN.NE	—	—	—	—	0.00%
DRUG.CNBright Minds Biosciences Inc.	$77.10	+9.22%	-10.98	$880.04M	0.00%
LOBE.CNLobe Sciences Ltd.	$0.06	+0.00%	-2.25	$24.65M	0.00%
MDMA.CNPharmala Biotech Holdings Inc.	$0.22	-12.00%	-27.00	$30.04M	0.00%

About BetterLife Pharma Inc.

BetterLife Pharma Inc., a biotechnology firm headquartered in Vancouver, Canada, specializes in researching and bringing to market therapeutic compounds designed to address neurological disorders across the globe. The company's core focus involves refining and advancing drug candidates derived from interferon-based technologies, which are intended to leverage the immune system to combat viral infections. Its diverse product pipeline includes BETR-001, targeting conditions such as major depressive disorder, treatment-resistant depression, cluster headaches, and post-traumatic stress disorder. Another candidate, BETR-002, is being developed for benzodiazepine dependency, anxiety, and spasticity. Furthermore, BetterLife Pharma is working on MM-003 for COVID-19 and other respiratory viral infections, MM-001 as a localized intravaginal cream for HPV-induced cervical intraepithelial neoplasia, and AP-002 for cancer treatment. The company also maintains a research collaboration with the University of California San Diego, conducting preclinical behavioral pharmacology studies on TD-0148A, a lysergic acid diethylamide derivative solution. Incorporated in 2002, the company operated as Pivot Pharmaceuticals Inc. before officially changing its name to BetterLife Pharma Inc. in December 2019.

BetterLife Pharma Inc. is headquartered in CA.

BetterLife Pharma Inc. (BETRF) stock trades at $0.15 with a market capitalization of $23.96M. The stock is valued at a negative price-to-earnings (P/E) ratio of -16.80, reflecting a net loss over the last twelve months, a negative price-to-book of -3.33, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.03 and $0.20, and currently trades 25.0% below its 52-week high.

On profitability, BetterLife Pharma Inc. generates a return on equity (ROE) of 19.88% (not meaningful, as shareholders' equity is negative), return on capital employed of 29.80%.

Official website: www.abetterlifepharma.com